Synonym
AZD-9164; AZD9164; 977LWC4O5D; CHEMBL1921904; J3.232.015E
IUPAC/Chemical Name
(R)-1-(4-fluorophenethyl)-3-(((S)-2-phenyl-2-(piperidin-1-yl)propanoyl)oxy)quinuclidin-1-ium
InChi Key
FNYFFCOCVNTJCD-NNMXADRKSA-N
InChi Code
InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1
SMILES Code
C[C@@](N1CCCCC1)(C(=O)O[C@H]2C[N+]4(CCC3=CC=C(F)C=C3)CCC2CC4)C5=CC=CC=C5
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
465.63
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bergenholm L, Collins T, Evans ND, Chappell MJ, Parkinson J. PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. J Pharmacol Toxicol Methods. 2016 May-Jun;79:34-44. doi: 10.1016/j.vascn.2016.01.002. PubMed PMID: 26780675.
2: Jorup C, Bengtsson T, Strandgården K, Sjöbring U. Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies. BMC Pulm Med. 2014 Mar 27;14:52. doi: 10.1186/1471-2466-14-52. PubMed PMID: 24669829; PubMed Central PMCID: PMC3976047.
3: Bjermer L, Bengtsson T, Jorup C, Lötvall J. Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respir Med. 2013 Jan;107(1):84-90. doi: 10.1016/j.rmed.2012.09.014. PubMed PMID: 23098686.
4: Silvester S, Zang F. Overcoming non-specific adsorption issues for AZD9164 in human urine samples: consideration of bioanalytical and metabolite identification procedures. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 15;893-894:134-43. doi: 10.1016/j.jchromb.2012.03.004. PubMed PMID: 22440890.
5: Mete A, Bowers K, Chevalier E, Donald DK, Edwards H, Escott KJ, Ford R, Grime K, Millichip I, Teobald B, Russell V. The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6. doi: 10.1016/j.bmcl.2011.10.002. PubMed PMID: 22047691.
